Hospital Acquired Infection Control Market Expected to be Valued US$ 10.1 Billion by the end of 2033, By Persistence Market Research
16 janv. 2024 05h45 HE | Persistence Market Research
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Hospital Acquired Infection Control Market: A Comprehensive Report Hospital Acquired Infections (HAIs) are infections acquired by patients during their...
GMILogo_Vertical-Gradient.png
Infection Control Surveillance Solutions Market to hit USD 1.7 Billion by 2030, says Global Market Insights Inc.
19 sept. 2022 03h10 HE | Global Market Insights Inc.
Selbyville, Delaware, Sept. 19, 2022 (GLOBE NEWSWIRE) -- The infection control surveillance solutions market value is poised to surpass USD 1.7 million by 2030, according to a new research report...
TIP_link_300x300.jpg
Sepsis Diagnostics Market Worth $1,226.52 Million, Globally, by 2028 at 9.2% CAGR - Exclusive Report by The Insight Partners
13 mai 2022 09h32 HE | The Insight Partners
New York, May 13, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product...
Phoenix Based BioNov
Phoenix Based BioNovelus Announces a New Product for the Health Disinfectant Industry
22 juin 2017 07h00 HE | BioNovelus Inc.
Phoenix, June 22, 2017 (GLOBE NEWSWIRE) -- / At the recent ExpoMed Show in Mexico City, BioNovelus (ONOV) Chairman and founder, Jean Ekobo, was proud to introduce the newest addition to the...
Melinta Therapeutics
Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens
06 sept. 2014 12h01 HE | Melinta Therapeutics
NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Hartford Hospital today announced in vitro results from an investigator-sponsored study that highlight delafloxacin's...